Drug Profile
RQ 00434739
Alternative Names: CMR-1 anatgonist - RaQualia Pharma; RQ-00434739Latest Information Update: 17 Jul 2023
Price :
$50
*
At a glance
- Originator RaQualia Pharma
- Class Analgesics; Anti-inflammatories; Small molecules
- Mechanism of Action TRPM8 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neuropathic pain
- Research Pain
- Discontinued Inflammation
Most Recent Events
- 14 Jul 2023 RQ 00434739 is still in preclinical development for Neuropathic pain (PO) in Japan (RaQualia Pharma pipeline, July 2023)
- 14 Jul 2023 RQ 00434739 is still in preclinical development for Pain (PO) in Japan (RaQualia Pharma pipeline, July 2023)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Neuropathic-pain in Japan (PO)